Literature DB >> 12175707

Urocortin has cell-proliferative effects on cardiac non-myocytes.

Keiichi Ikeda1, Katsuyoshi Tojo, Yutaka Oki, Kazuwa Nakao.   

Abstract

Urocortin (Ucn) is a member of the corticotropin-releasing hormone (CRH)-related peptides that has been reported to have cardiac inotropic and hypertrophic effects. In addition, Ucn mRNA was expressed in cardiac myocytes (MCs) and Ucn was suggested to have cardioprotective effects. Recently, it was reported that Ucn mRNA was expressed in cardiac non-myocytes (NMCs). Based on these facts, Ucn is assumed to affect not only MCs but also NMCs in an autocrine fashion. The present study was designed to elucidate a pathophysiological role of Ucn on NMCs. NMCs were prepared by the discontinuous Percoll gradient and adhesion method. Ucn increased [(3)H]-thymidine uptake into NMCs. Ucn also enhanced endothelin-1-induced increase of [(3)H]-thymidine uptake into NMCs. Effects of Ucn on [(3)H]-thymidine uptake into NMCs were significantly abolished by the protein kinase A inhibitor, H89 (10(-5) M), but not by a competitive antagonist of CRH receptors, astressin (10(-5) M). Ucn also increased intracellular cAMP accumulation more potently than CRH on a molar basis. Finally, both MCs and NMCs also secreted Ucn. Together with the recent findings, at least in NMCs, these data suggest that Ucn could exert its own actions via the cAMP signaling pathway, but not through known CRH type 2 receptors, in an autocrine fashion. In conclusion, the present study indicated that Ucn was secreted not only from MCs but also from NMCs and that the primary source of Ucn acting on heart was the heart itself. On the other hand, Ucn could proliferate NMCs as well as MCs, suggesting that Ucn could be involved in cardiac hypertrophy and fibrosis, i.e., cardiac remodeling, in spite of its putative cardioprotective actions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12175707     DOI: 10.1016/s0024-3205(02)01945-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases.

Authors:  Keiichi Ikeda; Katsuyoshi Tojo; Goro Tokudome; Makoto Ohta; Ken-ichi Sugimoto; Tadashi Tamura; Naoko Tajima; Seibu Mochizuki; Makio Kawakami; Tatsuo Hosoya
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

2.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

3.  Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system.

Authors:  Kazuhiro Takahashi
Journal:  Int J Endocrinol       Date:  2012-05-17       Impact factor: 3.257

4.  Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo.

Authors:  Akinori Hasegawa; Kengo Sato; Remina Shirai; Rena Watanabe; Keigo Yamamoto; Kaho Watanabe; Kyoko Nohtomi; Tsutomu Hirano; Takuya Watanabe
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

5.  Differentiation dependent expression of urocortin's mRNA and peptide in human osteoprogenitor cells: influence of BMP-2, TGF-beta-1 and dexamethasone.

Authors:  Mohammad Tezval; Hossein Tezval; Klaus Dresing; Ewa Klara Stuermer; Martina Blaschke; Klaus Michael Stuermer; Heide Siggelkow
Journal:  J Mol Histol       Date:  2009-12-01       Impact factor: 2.611

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.